# US 2015/0175983 A1 · Method for purifying transgenic factor vii

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175983 A1
- Document ID: US20150175983A1
- Status: Published application
- Kind: A1
- Application number: 14/415,254
- Filed: 2013-07-18
- Published: 2015-06-25
- Earliest claimed: 2012-07-19
- Assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
- Applicants: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
- Inventors: Damien Bataille; Michel Nogre
- Web page: https://patentgrep.com/patent/US20150175983A1

## CPC

- C12N 9/24: acting on glycosyl compounds (3.2)
- C07K 16/36: against blood coagulation factors
- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

An anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.

## Claims

### Claim 1

A method for purifying transgenic Factor VII (TgFVII) and/or transgenic activated Factor VII (TgFVIIa) from a source biological material, comprising a step of affinity chromatography comprising the steps of:
(a) contacting a source biological material containing TgFVII and/or TgFVIIa with a ligand which is specific to TgFVII and/or TgFVIIa, under conditions allowing the TgFVII and/or TgFVIIa to bind the ligand, and
(b) recovering TgFVII and/or TgFVIIa by disrupting in a non destructive way the interaction with said ligand.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said ligand is an antigen-binding protein directed to at least one TgFVII or TgFVIIa epitope, or a functional fragment or derivative thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said ligand comprises two heavy polypeptide chains forming two complete antigen binding sites and is devoid of light polypeptide chains.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said ligand is derived from heavy immunoglobulin chains of Camelidae.

### Claim 5 (depends on 1)

The method according to claim 1, wherein step (b) comprises at least one washing step for removing unbound material before eluting TgFVII or TgFVIIa from the ligand, and further optionally comprises a second washing step for removing weak bound material.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the source biological material is obtained from a transgenic animal producing TgFVII and/or TgFVIIa.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the animal is a mammal female, and preferably a rabbit female, and the source biological material is milk

### Claim 8 (depends on 7)

The method according to claim 7, further comprising the preliminary steps, before step (a), of collecting and clarifying milk.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the milk clarification step is performed by citrate salt addition, followed by filtration.

### Claim 10 (depends on 1)

The method according to claim 1, further comprising a step c) of chromatographic purification of the eluted TgFVII and/or TgFVIIa on an ion exchanger, and preferably on an anion exchanger, under conditions wherein TgFVII and/or TgFVIIa are retained on the ion exchanger.

### Claim 11 (depends on 1)

The method according to claim 1, further comprising a step d) of chromatographic separation of the eluted TgFVII and/or TgFVIIa on pseudo-affinity resin, and preferably on hydroxyapatite, under conditions wherein TgFVII and/or TgFVIIa are retained on the pseudo-affinity resin.

### Claim 12 (depends on 1)

The method according to claim 1, further comprising a step e) of chromatographic separation of the eluted TgFVII and/or TgFVIIa on a size exclusion support.

### Claim 13 (depends on 1)

The method according to claim 1, further comprising at least one step of eliminating and/or inactivating viruses, preferably by nanofiltration and/or by Solvent/Detergent treatment.

### Claim 14 (depends on 1)

The method according to claim 1, further comprising the final steps of formulating, sterilizing and lyophilizing the purified TgFVII and/or TgFVIIa.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the step of affinity chromatography comprises the steps of:
(a) loading a chromatographic resin on which a ligand as previously defined is immobilized, with milk from a transgenic female rabbit containing recombinantly produced TgFVII and/or TgFVIIa, under conditions allowing the ligand to bind TgFVII and/or TgFVIIa;
(b1) washing the unbound material;
(b2) washing the weak bound material; and
(b3) eluting TgFVII and/or TgFVIIa from the resin.

### Claim 16 (depends on 5)

The method according to claim 5, wherein, during said affinity chromatography step, said second washing step for removing weak bound material is performed with a buffer comprising from 10% to 50% of a hydrophobic agent, and the ionic strength of which is ranging from 200 to 600 mM.

### Claim 17 (depends on 5)

The method according to claim 5, wherein, during said affinity chromatography step, said elution step for eluting TgFVII and/or TgFVIIa from the resin is performed with a buffer comprising from 20% to 70% of a hydrophobic agent, and the ionic strength of which is ranging from 500 to 2500 mM.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the resulting purified transgenic FVII is an almost fully activated, high purity FVII, comprising a low percentage of degraded, proteolized or oxidized forms.

### Claim 19 (depends on 1)

The method according to claim 1, characterized in that the affinity chromatography step and/or of ion exchange chromatography step and/or of size exclusion chromatography step allow to obtain a viral reduction factor superior to 3 log10, preferably superior to 4 log10, more preferably superior to 5 log10.
